Neoadjuant chemoradiothrapy in treatment of proximal gastric cancer

Evaluation of resectability rate and tumor complete pathological response in patients with locally advanced proximal gastric cancers receiving neoadjuant chemoradiothrapy

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017070834945N1

Enrollment

Registered

2017-08-12

Start date

2016-01-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer. Stomach, unspecified

Interventions

Intervention Group (Concurrent chemoradiotherapy plus surgery): Patients undergo complete CT scan of the abdomen and pelvis to confirm the absence of metastasis. Following this, induction chemotherapy

Treatment - Drugs

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: performance status 0, 1 and 2; surgery in future treatment planning; and good condition for chemotherapy, radiotherapy and surgery. Exclusion criteria: metastasis; death.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Resectability of tumor or R0 resection. Timepoint: After 15 weeks of neoadjuant therapy. Method of measurement: Pathology report after surgery.	—

Secondary

Measure	Time frame
Myelosuppression. Timepoint: every 7 days during treatment. Method of measurement: complete blood count.;Nausea. Timepoint: On a weekly basis. Method of measurement: Based on the scale provided by Common Terminology Criteria for Adverse Events, Version 4.;Vomiting. Timepoint: On a weekly basis. Method of measurement: Based on the scale provided by Common Terminology Criteria for Adverse Events, Version 4.;Hair loss. Timepoint: On a weekly basis. Method of measurement: Based on the scale provided by Common Terminology Criteria for Adverse Events, Version 4.	—

Measure

Time frame

Myelosuppression. Timepoint: every 7 days during treatment. Method of measurement: complete blood count.;Nausea. Timepoint: On a weekly basis. Method of measurement: Based on the scale provided by Common Terminology Criteria for Adverse Events, Version 4.;Vomiting. Timepoint: On a weekly basis. Method of measurement: Based on the scale provided by Common Terminology Criteria for Adverse Events, Version 4.;Hair loss. Timepoint: On a weekly basis. Method of measurement: Based on the scale provided by Common Terminology Criteria for Adverse Events, Version 4.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Masume Masoudian

Mashhad University of Medical Sciences

MASOUDIANM941@MUMS.AC.IR+98 51 3842 8621

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026